Skip to main content

Day: August 1, 2024

Oaktree Specialty Lending Corporation Announces Third Fiscal Quarter 2024 Financial Results and Declares Quarterly Distribution of $0.55 Per Share

LOS ANGELES, CA, Aug. 01, 2024 (GLOBE NEWSWIRE) — Oaktree Specialty Lending Corporation (NASDAQ: OCSL) (“Oaktree Specialty Lending” or the “Company”), a specialty finance company, today announced its financial results for the fiscal quarter ended June 30, 2024. Financial Highlights for the Quarter Ended June 30, 2024  Total investment income was $95.0 million ($1.16 per share) for the third fiscal quarter of 2024, as compared with $94.0 million ($1.18 per share) for the second fiscal quarter of 2024. The increase was primarily driven by higher interest income as a result of the growth in the investment portfolio and higher original issue discount (“OID”) accretion driven by purchase premium acceleration in the prior quarter from the repayment of certain investments acquired in the mergers with Oaktree Strategic Income Corporation...

Continue reading

Calfrac Reports Second Quarter 2024 Results

CALGARY, Alberta, Aug. 01, 2024 (GLOBE NEWSWIRE) — Calfrac Well Services Ltd. (“Calfrac” or “the Company”) (TSX: CFW) announces its financial and operating results for the three and six months ended June 30, 2024. The following press release should be read in conjunction with the management’s discussion and analysis and interim consolidated financial statements and notes thereto as at June 30, 2024. Readers should also refer to the “Forward-looking statements” legal advisory and the section regarding “Non-GAAP Measures” at the end of this press release. All financial amounts and measures are expressed in Canadian dollars unless otherwise indicated. Additional information about Calfrac is available on the SEDAR+ website at www.sedarplus.ca, including the Company’s Annual Information Form for the year ended December 31, 2023. CEO’S...

Continue reading

Cenovus announces second quarter 2024 results

CALGARY, Alberta, Aug. 01, 2024 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) delivered strong operational performance across its portfolio in the second quarter of 2024, with solid production from its upstream assets and improved crude throughput at the company’s U.S. refineries, which operated at an overall utilization rate of 93%. Net debt was $4.26 billion at June 30, 2024, and in July the company achieved its net debt target of $4.0 billion. As a result, beginning in the third quarter, Cenovus will begin returning 100% of excess free funds flow (EFFF) to shareholders, as per the company’s shareholder returns framework. “With the achievement of this significant financial milestone, we are now in a position to substantially increase our shareholder returns,” said Jon McKenzie, Cenovus President & Chief Executive...

Continue reading

Patria Reports Second Quarter 2024 Earnings Results

GRAND CAYMAN, Cayman Islands, Aug. 01, 2024 (GLOBE NEWSWIRE) —  Patria (Nasdaq:PAX) reported today its unaudited results for the second quarter ended June 30, 2024. The full detailed presentation of Patria’s second quarter 2024 results can be accessed on the Shareholders section of Patria’s website at https://ir.patria.com/. Alex Saigh, Patria’s CEO, said: “The 2nd quarter of 2024 was a very busy quarter as we continued to make solid progress towards our near and long-term goals. Fee Related Earnings reached $40 million dollars, representing a 17% increase from 2Q23. We delivered close to $34 million dollars of Distributable Earnings, or 22 cents per share. We continued to grow and diversify our platform as we organically raised $2.2 billion dollars over the first half of 2024 and approximately $5 billion over the last twelve...

Continue reading

Axalta Releases Second Quarter 2024 Results

PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) — Axalta Coating Systems Ltd. (NYSE: AXTA) (“Axalta”), a leading global coatings company, announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights:Net sales increased 4.4% year over year to $1.35 billion Net income increased $52 million year over year to $113 million Adjusted EBITDA increased $64 million year over year to $291 million with Adjusted EBITDA margin improving 400 basis points year over year to 21.5% Diluted EPS increased 89% year over year to $0.51 and Adjusted Diluted EPS increased 63% year over year to $0.57 Net leverage ratio of 2.6x Repurchased $50 million of common shares Increased full year 2024 earnings and free cash flow outlook Hosted Strategy Day outlining three-year plan for accelerating performanceSecond Quarter...

Continue reading

Teleflex Reports Second Quarter Financial Results and Full Year 2024 Outlook

Announces $500 million share repurchase authorization inclusive of a $200 million accelerated share repurchase of common stock WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2024. Second quarter financial summaryGAAP revenue of $749.7 million, up 0.9% compared to the prior year periodAdjusted revenue of $763.5 million, excluding the impact from increases in our reserves related to the Italian payback measure pertaining to prior years, up 2.7% compared to the prior year period, up 3.4% on a constant currency basis.1GAAP diluted EPS from continuing operations of $1.69, compared to $2.35 in the prior year periodAdjusted diluted EPS from continuing operations of $3.42, compared to $3.41 in the prior year...

Continue reading

Apollo Reports Second Quarter 2024 Results

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) — Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo”) today reported results for the second quarter ended June 30, 2024. Marc Rowan, Chief Executive Officer at Apollo said, “We generated record fee related earnings in the second quarter behind particularly strong momentum in Asset Management. The business produced record levels of quarterly debt origination, gross capital deployment, and third-party fundraising excluding flagship private equity. In Retirement Services, Athene’s compelling profitability is attracting significant amounts of third-party capital to support continued growth following the highly successful fundraise for ADIP II – the largest equity sidecar in the industry.” Apollo issued a full detailed presentation of its second...

Continue reading

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

– ACTIVATE-KidsT is Agios’ First Pediatric Data Readout;Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adultswith PK Deficiency Who are Regularly Transfused – – Prespecified Statistical Criterion for the Primary Endpoint in ACTIVATE-KidsT Was Not Met; Results Were Clinically Meaningful, with Observed Response Rates Higher for Mitapivat than Placebo for the Primary Endpoint of Transfusion Reduction Response and for the Secondary Endpoints of Transfusion-Free Response and Normal Hemoglobin Response – – Enrollment Completed for Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with PK Deficiency Who Are Not Regularly Transfused; Topline Data Expected in 2025 – CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate...

Continue reading

Regeneron Reports Second Quarter 2024 Financial and Operating Results

Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023 Second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 27% to $3.56 billion versus second quarter 2023 Second quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® increased 2% to $1.53 billion versus second quarter 2023, including $304 million from EYLEA HD Second quarter 2024 Libtayo® global net sales increased 42% to $297 million versus second quarter 2023 Second quarter 2024 GAAP diluted EPS increased 46% to $12.41 and non-GAAP diluted EPS(a) increased 13% to $11.56 versus second quarter 2023; second quarter 2024 includes unfavorable $0.18 impact from acquired IPR&D charge European Commission approved Dupixent as first-ever biologic therapy for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by...

Continue reading

Compass Pathways announces second quarter 2024 financial results and business highlights

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024Gino Santini to join Board of Directors as ChairmanLori Englebert named new Chief Commercial OfficerCash position of $228.6 millionConference call August 1 at 8:00 am ET (1:00 pm UK)LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2024 and an update on recent business progress. “As we continue to advance our phase 3 program in treatment-resistant depression, we are pleased to expand the breadth and depth of experience across our executive and leadership teams with the additions...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.